Two Research Studies Supported by Medidata to be Presented at ASH 2018
November 20 2018 - 8:30AM
Business Wire
- Medidata Rave Omics Machine Learning
Identifies New Evidence of Biomarkers in Rare Disease Research by
the Castleman Disease Collaborative Network
- Memorial Sloan Kettering Cancer Center
(MSK) Monitors Newly Diagnosed Myeloma Patients with Medidata
ePRO
The Castleman Disease Collaborative Network (CDCN) will present
results of a large-scale proteomics study of idiopathic
multicentric Castleman disease (iMCD), supported by Medidata Rave
Omics, at the 60th Annual Meeting of the American Society of
Hematology. The CDCN will also share an overview of its poster
presentation and abstract at the Medidata (NASDAQ: MDSO) booth
(#257).
The CDCN, a global non-profit organization dedicated to
accelerating research and treatments for Castleman disease, in
collaboration with Medidata Rave Omics, will share an overview of
its serum proteomics study abstract at the Medidata booth on
December 2 at 2 p.m. The CDCN’s research findings presented at ASH
include:
- Identification of six proteomically
unique iMCD disease subtypes or disease states
- Evidence of proteomic predictors of
anti-interleukin-6 treatment response
- Etiological insights into the poorly
understood rare disease
CDCN and Medidata speakers:
- Dustin Shilling, Castleman Disease
Collaborative Network
- David Lee, chief data officer,
Medidata
Memorial Sloan Kettering Cancer Center (MSK) will also present
new research supported by the Medidata Rave Patient Cloud at ASH.
The aim of the study is to assess whether the use of mobile
wearable technology establishes patterns of “sleep” and “wake”
states in newly diagnosed patients receiving therapy, and if these
patterns differ over time. Activity, sleep data, and completed
patient reported outcome (ePRO) questionnaire data were
automatically synced and transferred to the Medidata Rave
platform.
Learn more about Medidata at ASH 2018.
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
About Castleman Disease Collaborative Network (CDCN)
CDCN is a global initiative dedicated to accelerating research
and treatment for Castleman disease (CD) to improve survival for
all patients with CD. The CDCN’s innovative approach first involved
building a global community of over 400 physicians and researchers,
assembling a scientific advisory board of 28 experts from eight
countries, and supporting and engaging patients in research
prioritization. Then, the CDCN crowdsourced among the global
community to identify gaps in medical knowledge and determine high
priority research projects. In parallel, the CDCN connects and
supports thousands of CD patients around the world. Now, the CDCN
recruits top researchers to conduct studies, and works with
patients, loved ones, and the public to raise funding to enable
these studies. More information is available at: www.CDCN.org
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005354/en/
Medidata:Investors:Betsy Frank, +1
917-522-4620bfrank@mdsol.com
Media:Erik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024